Centessa Pharmaceuticals plc
CNTANASDAQHealthcare● Active
$39.63
+$0.01(+0.01%)
Market Cap$6.1B
P/E Ratio—
52W High$40.26
52W Low$10.95
Centessa Pharmaceuticals plc (CNTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CNTA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.52
Est. -$0.38 · -36.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
CNTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.40 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.38 | -$0.52 | -36.8% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.37 | -$0.48 | -29.2% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.39 | -$0.41 | -5.1% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.35 | -$0.38 | -8.6% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.35 | -$0.20 | +42.9% | $0.01B | $0.00B | +600.0% |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$0.38 | -$0.34 | +10.5% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.42 | -$0.37 | +11.9% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.52
EPS Est.
-$0.38
EPS Surpr.
-36.8%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.48
EPS Est.
-$0.37
EPS Surpr.
-29.2%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.39
EPS Surpr.
-5.1%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.38
EPS Est.
-$0.35
EPS Surpr.
-8.6%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.35
EPS Surpr.
+42.9%
Revenue
$0.01B
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.38
EPS Surpr.
+10.5%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.37
EPS Est.
-$0.42
EPS Surpr.
+11.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.42 | $-0.42 | $-0.42 | 2 |
| Q3 FY2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q2 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2027 | $-0.42 | $-0.42 | $-0.42 | 2 |
| Q4 FY2026 | $-0.43 | $-0.43 | $-0.43 | 2 |
| Q3 FY2026 | $-0.44 | $-0.43 | $-0.42 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -36.8% | $39.70 | $39.67 | -0.08% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -29.2% | $27.58 | $39.72 | +44.02% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -5.1% | $23.74 | $22.52 | -5.14% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -8.6% | $16.61 | $17.11 | +3.01% |
| ▲ Q2 FY2025 | May 14, 2025 | +42.9% | $12.46 | $12.27 | -1.52% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +10.5% | $15.75 | $16.63 | +5.59% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +11.9% | $16.73 | $17.00 | +1.61% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -5.3% | $10.55 | $11.01 | +4.36% |
Q2 FY2026-0.08%
Report Date
May 5, 2026
EPS Beat/Miss
-36.8%
Price Before
$39.70
Price After
$39.67
Q1 FY2026+44.02%
Report Date
Mar 31, 2026
EPS Beat/Miss
-29.2%
Price Before
$27.58
Price After
$39.72
Q4 FY2025-5.14%
Report Date
Nov 5, 2025
EPS Beat/Miss
-5.1%
Price Before
$23.74
Price After
$22.52
Q3 FY2025+3.01%
Report Date
Aug 12, 2025
EPS Beat/Miss
-8.6%
Price Before
$16.61
Price After
$17.11
Q2 FY2025-1.52%
Report Date
May 14, 2025
EPS Beat/Miss
+42.9%
Price Before
$12.46
Price After
$12.27
Q1 FY2025+5.59%
Report Date
Mar 24, 2025
EPS Beat/Miss
+10.5%
Price Before
$15.75
Price After
$16.63
Q4 FY2024+1.61%
Report Date
Nov 12, 2024
EPS Beat/Miss
+11.9%
Price Before
$16.73
Price After
$17.00
Q3 FY2024+4.36%
Report Date
Aug 13, 2024
EPS Beat/Miss
-5.3%
Price Before
$10.55
Price After
$11.01
Avg Beat Reaction+1.89%
Avg Miss Reaction+9.23%
Beat Rate3 / 8 quarters
Largest Move+44.02% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CNTA ends December
Centessa Pharmaceuticals plc (CNTA) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.52 — missing the analyst consensus of $-0.38 by -36.8%. The next CNTA earnings date is expected around September 1, 2026.
Each quarter, investors track CNTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CNTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CNTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CNTA earnings · 5 questionsCentessa Pharmaceuticals plc's next earnings report is expected around September 1, 2026. CNTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CNTA historically reports after market close (AMC).
CNTA earnings datewhen is CNTA earningsCNTA next earnings datewhen does CNTA report earningsCNTA earnings calendar
▸ Source: FMP · Centessa Pharmaceuticals plc SEC filings · US GAAP · Centessa Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026